Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva

Allergan announced over the weekend that it agreed to pay $560m plus undisclosed milestone fees for novel depression drug developer Naurex, but the company remained quiet about the rumored sale of its generics business to Teva Pharmaceutical Industries for several billion dollars.